secured debt
Royalty Pharma Commits $2 Billion to Revolution Medicines for RAS Cancer Drug Development
Royalty Pharma; Revolution Medicines; daraxonrasib; $2 billion funding; RAS cancer; synthetic royalty; secured debt; clinical development; oncology; biotech funding